Alector (ALEC) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Alector (ALEC) over the past year, losing 28.4% versus a loss of 37.5%. Over five years, KROS leads with a -71.2% price change compared with -91.8% for ALEC. Keros Therapeutics is the larger company by market cap ($228.2 million vs $221.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | KROS |
|---|---|---|
| Share price | $1.99 | $11.51 |
| Market cap | $221.64M | $228.21M |
| 1-day change | +3.39% | +2.68% |
| YTD return | +23.08% | -44.94% |
| 1-year return | -37.46% | -28.37% |
| 5-year return | -91.76% | -71.25% |
| EPS (TTM) | $-1.09 | $-3.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $22.55 |
| 52-week low | $1.09 | $9.69 |
| Distance from 52-week high | -41.62% | -48.96% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +66.25% | +72.28% |
| Average volume | 2.77M | 196.01K |
| Shares outstanding | 111.66M | 19.83M |
| Employees | 103 | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
ALEC vs KROS FAQ
Which is bigger, Alector or Keros Therapeutics?
Keros Therapeutics (KROS) is larger, with a market capitalization of $228.21M compared with $221.64M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or KROS?
KROS returned -28.37% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Keros Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for Keros Therapeutics.